Auriculin anaritide: Began Phase III trial in 250 patients, with primary end point of dialysis-free survival for 21 days. The 18-24 month trial also will evalua

In a previous Phase III study, Auriculin didn't reduce the need for dialysis in a broad patient population; however the drug significantly reduced the need for dialysis and significantly improved 21-d...